Sep 30

Scientific

LBA 01 - Late Breaking Abstracts

Room 22/23

02:30pm - 03:45pm PT

Special Session

Medical students

First-time Attendees

MODERATOR(S)

Beth Beadle, MD, PhD, FASTRO - Stanford University

Rachel Jimenez, MD, FASTRO - Massachusetts General Hospital

Credits

AMA PRA Category 1 Credits:

1.25

Presentations

02:30pm - 02:39pm PT

Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Speaker: Benjamin Movsas, MD, FASTRO - Henry Ford Cancer Institute, Detroit
02:39pm - 02:48pm PT

A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: final results from RTOG 3506 (STEEL)

Speaker: Edwin Posadas, MD - Cedars-Sinai Medical Center, Los Angeles
02:48pm - 02:57pm PT

Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)

Speaker: Ragu Ratnakumaran, MBBS - Royal Marsden NHS Foundation Trust, Sutton
02:57pm - 03:06pm PT

Addition of Metastasis-Directed Therapy to Standard of Care: Primary Aggregate Analysis and Immunologic Correlatives of the Phase II Randomized EXTEND Trial

Speaker: Alexander Sherry, MD - Mayo Clinic Rochester, Rochester
03:06pm - 03:15pm PT

Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Inoperable Locally Advanced Breast Cancer: A Phase 2 Randomized Trial (NEOTRAC)

Speaker: Priya Iyer, MD, MBBS - Cancer Institute (WIA), CHENNAI
03:15pm - 03:24pm PT

Baseline and Time-Dependent Predictors of Cognitive Decline for Brain Metastasis Patients Treated with Radiotherapy- A Secondary Analysis of the ATHENA Trial

Speaker: Haley Perlow, MD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland
03:24pm - 03:33pm PT

Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689

Speaker: Nancy Lee, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York
03:33pm - 03:42pm PT

Signal-Seeking P2R Trial of Proton or IMRT Dose Intensification in GBM: NRG-BN001

Speaker: Minesh Mehta, MD, MB, ChB, FASTRO - Miami Cancer Institute- Baptist Health South Florida, Miami